Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13860177 | 0.97 | CYP2B6 (0.35) | CYP2B6 | |
| SCHEMBL19520207 | 0.97 | CYP2B6 (0.35) | CYP2B6 | |
| SCHEMBL15514768 | 0.94 | — | — | |
| SCHEMBL15515320 | 0.81 | — | — | |
| SCHEMBL20416441 | 0.80 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL1266718 | 0.77 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL5430692 | 0.74 | CYP2B6 (0.30) | CYP2B6 | |
| SCHEMBL15515285 | 0.74 | ALDH1A1 (0.40) | — | |
| SCHEMBL15515185 | 0.74 | HSD11B1 (0.34) | — | |
| SCHEMBL20399278 | 0.74 | CHRM3 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181567-B9 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240174676-A1 | Pyrazolopyrimidine compounds as kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-110248949-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2023-02-17 | — | — | CN | disclosed |
| US-20220073522-A1 | Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11154563-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-11154563-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-11040980-B2 | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3571208-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200190092-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-11-07 | — | — | US | disclosed |
| CN-104822681-A | Pyrazolopyrimidine compounds as kinase inhibitors | PRINCIPIA BIOPHARMA INC | 2015-08-05 | — | — | CN | disclosed |
| EP-2892900-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2015-07-15 | — | — | EP | disclosed |
| US-20150094295-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2015-04-02 | — | — | US | disclosed |
| US-8940744-B2 | Pyrazolopyrimidine compounds as kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140364410-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2014-12-11 | — | — | US | disclosed |
| WO-2014039899-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-0190685-B1 | HETEROCYCLIC AMIDES | G.D. Searle & Co. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-4981853-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS | G. D. SEARLE & CO. (US) | 1991-01-01 | — | — | US | disclosed |
| EP-0190685-A2 | Heterocyclic amides | G.D. Searle & Co. (US) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040980-B2 | Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors | BTK, LCK, SYK | CYP2B6 1122/4885 |
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | CYP2B6 52/4885 |
| US-11154563-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | CYP2B6 3826/4885 |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | CYP2B6 3826/4885 |
| US-20200190092-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS KINASE INHIBITORS | BTK, SYK, LCK | CYP2B6 746/4885 |
| US-20140364410-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, SYK | CYP2B6 541/4885 |
| US-20150094295-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, SYK | CYP2B6 527/4885 |
| US-20220073522-A1 | Substituted Pyrazolo[3,4-d]Pyrimidines as Kinase Inhibitors | BTK, SYK, LCK | CYP2B6 746/4885 |
| US-20240174676-A1 | Pyrazolopyrimidine compounds as kinase Inhibitors | BTK, LCK, LYN | CYP2B6 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.